Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats

被引:64
作者
Abraham, Premila [1 ]
Kolli, Viswa Kalyan [1 ]
Rabi, Suganthy
机构
[1] Christian Med Coll & Hosp, Dept Biochem, Vellore 632002, Tamil Nadu, India
关键词
melatonin; methotrexate; nephrotoxicity; oxidative stress; rats; HIGH-DOSE METHOTREXATE; LIPID PEROXIDES; GLUTATHIONE; ANTIOXIDANT; RESCUE; 7-HYDROXYMETHOTREXATE; LEUCOVORIN; INJURY; LIVER;
D O I
10.1002/cbf.1676
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nephrotoxicity is an adverse side effect of methotrexate (MTX) chemotherapy. The present study verifies whether melatonin, an endogenous antioxidant prevents MTX-induced renal damage. Adult rats were administered 7 mg/kg body weight MTX intraperitoneally for 3 days. In the melatonin pretreated rats, 40 mg/kg body weight melatonin was administered daily intraperitoneally 1 h before the administration of MTX. The rats were killed 12 h after the final dose of MTX/vehicle. The kidneys were used for light microscopic and biochemical studies. The markers of oxidative stress were measured along with the activities of the antioxidant enzymes and myeloperoxidase activity in the kidney homogenates. Pretreatment with melatonin reduced MTX induced renal damage both histologically and biochemically as revealed by normal plasma creatinine levels. Melatonin pretreatment reduced MTX induced oxidative stress, alteration in the activity of antioxidant enzymes as well as elevation in myeloperoxidase activity. The results suggest that melatonin has the potential to reduce MTX induced oxidative stress, neutrophil infiltration as well as renal damage. As melatonin is an endogenous antioxidant and is non-toxic even in high doses it is suggested that melatonin may be beneficial in minimizing MTX induced renal damage in humans. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:426 / 433
页数:8
相关论文
共 53 条
[1]   METHOTREXATE-INDUCED RENAL IMPAIRMENT - CLINICAL-STUDIES AND RESCUE FROM SYSTEMIC TOXICITY WITH HIGH-DOSE LEUCOVORIN AND THYMIDINE [J].
ABELSON, HT ;
FOSBURG, MT ;
BEARDSLEY, P ;
GOORIN, AM ;
GORKA, C ;
LINK, M ;
LINK, D .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (03) :208-216
[2]   HIGH-DOSE METHOTREXATE - A CRITICAL REAPPRAISAL [J].
ACKLAND, SP ;
SCHILSKY, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) :2017-2031
[3]  
AEBI H, 1984, METHOD ENZYMOL, V105, P121
[4]   METHOTREXATE-INDUCED RENAL-FAILURE AND INEFFECTIVENESS OF PERITONEAL-DIALYSIS [J].
AHMAD, S ;
SHEN, F ;
BLEYER, WA .
ARCHIVES OF INTERNAL MEDICINE, 1978, 138 (07) :1146-1147
[5]  
AWASTHI YC, 1980, BIOCHEM J, V191, P1
[6]   Methotrexate causes oxidative stress in rat kidney tissues [J].
Devrim, E ;
Çetin, R ;
Kiliçoglu, B ;
Ergüder, BI ;
Avci, A ;
Durak, I .
RENAL FAILURE, 2005, 27 (06) :771-773
[7]   Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity [J].
Diaz-Granados, N ;
Howe, K ;
Lu, J ;
McKay, DM .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (06) :2169-2177
[8]  
DJERASSI I, 1975, CANCER CHEMOTH REP 3, V6, P3
[9]   Rheumatoid arthritis: An overview of new and emerging therapies [J].
Doan, T ;
Massarotti, E .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (07) :751-762
[10]  
Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498